The Week

APO.US fell 2.38% this week to close at $125.91, with a weekly range of 5.67%. The S&P 500 slipped just 0.08% over the same period, leaving APO.US roughly 2.3 percentage points behind the market. Day by day, the stock opened higher on Monday (Sep 14) and pushed toward $130 before retreating over Tuesday and Wednesday. Wednesday (Sep 16) marked the low near $122.72, and while Thursday and Friday saw some back-and-forth, the stock still finished at $125.91—a week of failed rallies and a lower centre of gravity.

Key Events

Apollo’s news flow this week centred on capital moves and asset reshuffling. Early in the week, reports said the company was in talks to acquire Johnson & Johnson’s orthopedics unit. Apollo funds also completed a €3 billion capital solution for Bayer and provided $585 million in financing to The Executive Centre. Thursday brought the heaviest flow of headlines: Apollo began investing in AI and related hardware startups, was reported to be considering raising its SoftBank loan to $9 billion to back the latter’s OpenAI investment, and was said to be exploring sale options for floating LNG infrastructure operator Energos. At the same time, Apollo cautioned that hyperscaler debt is flashing warning signals.

Analyst Ratings

Coverage on APO.US stands at 21 institutions, with 11 at buy, 4 at overweight and 6 at hold; none rate it underweight or sell. The consensus rating is buy, and the consensus target price is $153.47, about 21.9% above this week’s close of $125.91. Targets range from $130 to $173, pointing to wide dispersion. Within the diversified financial services industry, APO.US ranks first by analyst coverage, well ahead of the peer average.

The Week Ahead

Next week brings a fairly busy macro calendar: the Richmond Fed composite index on Tuesday, weekly oil inventories on Wednesday, then initial jobless claims and new home sales on Thursday. For Apollo specifically, the bigger watch items are the threads left open this week—the loan arrangement around SoftBank’s OpenAI investment, talks on J&J’s orthopedics business, and the potential sale of Energos. Any follow-through on these fronts could become a fresh driver.

In Short

This week’s price action and news flow point to a split picture. The stock lagged the market while the consensus rating remains buy, with the consensus target sitting about 21.9% above spot. Valuation runs near 39x P/E and 3.79x P/B, and the company is moving frequently across AI hardware, OpenAI-linked financing and potential asset deals. The question ahead is whether execution on these fronts can keep pace with how the multiple digests. On the latest trading day, large-lot money turned net seller while small-lot flow ran net buyer—a structural gap worth watching alongside the next moves in price.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.